EFPIA公布-您的问题已得到解答

The EFPIA disclosure requirementsfor healthcare professionals Your questions answeredJune 2025 Contents Working together: why do the pharmaceutical industryand healthcare professionals work together? About the disclosure provisions in the EFPIA code4 About data privacy 10 General information and questions 14 Working together: why do the pharmaceuticalindustry and healthcare professionals worktogether? Why does industry pay health professionalsto provide services? Collaboration between industry and healthcare professionals (HCPs) benefitspatients. It is a relationship that has delivered numerous innovative medicinesand changed the way many diseases impact on our lives. Industry and healthprofessionals collaborate in a range of activities from clinical research, sharingbest clinical practice and exchanging information on how new medicines fit intothe patient pathway. What services to health professionals doesthe industry provide? Industry works with healthcare professionals to advance patient care. Collaborationbetween industry and health professionals benefits patients. It is a relationship thathas delivered numerous innovative medicines and changed the way many diseasesimpact on our lives. Companies can shape their future research programmes based on the scientificand medical expert opinion of HCPs. For example, ensuring studies are developedin the right way to enable a meaningful assessment of clinical benefit. Understanding how a medicine would be used in clinical practice can helpcompanies provide the right information, education and training, to supportthe introduction of a new medicine, to ensure the best outcomes for patients. About the disclosure provisions in the EFPIAcode What are the disclosure provisions in the EFPIAcode? The Disclosure provisions in the EFPIA Code require all EFPIA member companiesand companies that are members of EFPIA member associations to disclosetransfers of value to HCPs, HCOs and POs. Under these provisions, EFPIA membercompanies will have to disclose the names of HCPs and HCOs that have receivedpayments or other transfers of value from them. They will also have to disclose –by HCP or HCO – the total amounts of value transferred, by type of activity, whichcould consist of, for instance, a grant to an HCO, a consultancy fee for speaking,payment for travel, or registration fees to attend a medical congress. Since 30 June 2016, companies disclose transfers of value made to HCPs, suchas consultancy and advisory boards, speaker fees, and sponsorship to attendmeetings. This transformational step in the relationship between industry andhealth professionals is a result of the EFPIA Disclosure Requirements. Why has EFPIA introduced the public disclosureof payments to health professionals? Collaboration between industry and health professionals benefits patients.It is a relationship that has delivered numerous innovative medicines and changedthe way many diseases impact on our lives. Industry and health professionalscollaborate in a range of activities from clinical research, sharing best clinicalpractice and exchanging information on how new medicines fit into the patientpathway. Bringing greater transparency to this, already well-regulated, vitalrelationship is about strengthening the basis for collaboration in the future.Society has increasingly high expectations for transparency, none more so thanin healthcare. We want to ensure we meet those expectations going forward. Which countries does the EFPIA code cover? The EFPIA Code covers the 36 countries within its membership (see www.efpia.eu),EU, EEA and EFTA countries and beyond, as well as countries that decideto voluntarily abide by the Code – it covers the geographical area from Portugalto Ukraine, from Turkey to Iceland, and from Greece to Scandinavian countries. What types of payments are disclosed? Companies disclose payments made to health professionals such as consultancy,advisory boards, speaker fees and sponsorship to attend meetings. More specifically, donations and grants (to organisations only; grants and donationsare not legally allowed to individual healthcare professionals), fees-for-service& consultancy, where a contract is in place for activities such as speaking at,or chairing meetings, attending advisory boards and media consultancy, coverage ofcosts to participate in events (including registration fees, travel and accommodation)and research & development transfers of value, which are disclosed in aggregate. Does the system cover all payments to healthcareprofessionals at an individual level? No. Payments made for research and development activities are disclosedin aggregate. For the purposes of the disclosure, these activities are definedas transfers of value to HCPs or HCOs related to the planning or conduct of:•non-clinical studies(as defined in OECD Principles on Good Laboratory Practice);•clinical trials(as defined in Directive 2001/20/EC); or•non-interventional studiesthat a